{
  "slug": "kopra-bio",
  "name": "Kopra Bio",
  "yc_id": 29714,
  "batch": "Summer 2024",
  "website": "https://kopra.bio",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:31:53.104717",
    "website": "https://kopra.bio",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 3870.73,
      "final_url": "https://www.kopra.bio/",
      "redirected": true,
      "checked_at": "2025-10-17T01:31:56.975456"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "kopra.bio",
      "error": "Whois command returned no output"
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": false,
      "x_frame_options": true,
      "x_content_type_options": true,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 50,
      "server": "Squarespace"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:42:12.517361",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:55:05.623201",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Immunotherapy revolution in oncology",
        "Personalized cancer treatment adoption",
        "Viral vector therapy advancement"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary genetically engineered virus technology developed at UCSF with demonstrated 90% survival improvement",
      "differentiation": "Viral-based immune system training approach vs traditional checkpoint inhibitors",
      "competitive_advantages": [
        "Strong preclinical efficacy data",
        "UCSF research pedigree",
        "Focus on high unmet need indication"
      ],
      "competitive_vulnerabilities": [
        "Small team size",
        "Early stage technology",
        "Regulatory pathway uncertainty"
      ]
    },
    "business_model": {
      "revenue_model": "Biopharmaceutical licensing/royalties",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "pre-seed",
      "growth_indicators": [
        "Impressive preclinical results",
        "Y Combinator backing",
        "Large addressable market"
      ],
      "growth_bottlenecks": [
        "Clinical trial funding requirements",
        "Regulatory approval timeline",
        "Manufacturing scalability"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Clinical trial failure",
        "Regulatory rejection",
        "Manufacturing complexity",
        "Competition from Big Pharma"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Breakthrough technology potential",
        "Massive market opportunity",
        "Strong scientific foundation"
      ],
      "concerns": [
        "Very early stage",
        "High capital requirements",
        "Long development timeline"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Moderna",
        "BioNTech",
        "Iovance Biotherapeutics"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Secure Series A funding for IND-enabling studies",
        "Expand team with regulatory and clinical expertise"
      ],
      "expansion_opportunities": [
        "Additional cancer indications",
        "Combination therapy approaches",
        "International market expansion"
      ]
    },
    "tokens_used": {
      "input": 716,
      "output": 562,
      "total": 1278,
      "estimated_cost": 0.010578
    },
    "status": "success"
  },
  "phase8_complete": true
}